Ionis Pharmaceuticals: A letter to the Angelman syndrome community.
Ionis addresses community questions following the ASPIRE trial results, reaffirming its commitment to obudanersen (ION582) through the HALOS, REVEAL, and CHAMPION trials
Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome
Ionis completes enrollment for Cohort 1 of the pivotal Phase 3 REVEAL study evaluating obudanersen for Angelman syndrome. Cohort 2 screening continues for ages 18–50.
First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome
Ionis Pharmaceuticals has dosed the first participant in its global Phase 3 REVEAL trial, evaluating the safety and efficacy of ION582 as a potential treatment for Angelman syndrome.
IONIS REVEAL Phase 3 Clinical Trial Update
The next chapter for ION582 is here: Ionis’ Phase 3 REVEAL trial is now listed, marking an important step toward a potential treatment for Angelman syndrome. Join FAST, ASF, and Ionis to learn what comes next.
Ionis Pharmaceuticals releases information on their planned phase 3 clinical trial for Angelman syndrome
Ionis Pharmaceuticals announces ION582 will advance into Phase 3, called REVEAL, with details to be presented at the FAST Global Science Summit on November 9th.